RECRUITING

Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain

Conditions

Sickle Cell Disease Vaso-occlusive Pain Episodes virtual reality adjunctive therapy opiate consumption pain reduction

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this randomized control clinical trial is to learn if virtual reality can be used to treat sickle cell pain in children. The main questions it aims to answer are: Does virtual reality reduce pain severity during a child's hospital stay for a vaso-occlusive pain crisis? Does virtual reality decrease the daily use of opiates? Researchers will compare standard therapy to the use of standard therapy plus a daily virtual reality experience to see if virtual reality works to treat sickle cell pain. All patients will: - Be asked to fill out a pain assessment survey three times daily for up to 3 days If randomized to intervention arm, patients will: * Participate in an immersive virtual reality experience once daily for up to 3 days * Fill out a survey twice daily to monitor for side effects from virtual reality experience * Fill out a satisfaction survey once during the study period

Official Title

Changing the View of Pain: Using Virtual Reality As Adjunctive Therapy for Sickle Cell Pain in Pediatric Patients

Quick Facts

Study Start:2024-09-12

Study Completion:2025-12-19

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06773715

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:8 Years to 21 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT

Inclusion Criteria	Exclusion Criteria
1. Patient ≥ 8 up to 21 years of age 2. Presenting to CHNOLA ER or outside facility with chief complaint of vaso-occlusive pain crisis, requiring inpatient admission for further pain management 3. No known cognitive or neurological deficits 4. Parental/guardian permission (informed consent) and if appropriate, child assent.	1. Patients aged 7-years-old and younger. 2. Patents upon admission found to have sequela of their sickle cell disease that would require medical therapy greater than the standard of care for a vaso-occlusive pain event. This includes acute chest syndrome, splenic sequestration, post-operative pain, and/or cerebrovascular accident 3. Patients who are developmentally or cognitively incapable of using VR equipment and answering questions appropriately 4. Failure to obtain or refusal to provide parental/guardian permission (informed consent) and if appropriate child assent 5. Patient has previously participated in the study 6. Study team is unable to initiate study interventions within the first 24 hours of a patient's admission

Inclusion Criteria

Exclusion Criteria

1. Patient ≥ 8 up to 21 years of age
2. Presenting to CHNOLA ER or outside facility with chief complaint of vaso-occlusive pain crisis, requiring inpatient admission for further pain management
3. No known cognitive or neurological deficits
4. Parental/guardian permission (informed consent) and if appropriate, child assent.

1. Patients aged 7-years-old and younger.
2. Patents upon admission found to have sequela of their sickle cell disease that would require medical therapy greater than the standard of care for a vaso-occlusive pain event. This includes acute chest syndrome, splenic sequestration, post-operative pain, and/or cerebrovascular accident
3. Patients who are developmentally or cognitively incapable of using VR equipment and answering questions appropriately
4. Failure to obtain or refusal to provide parental/guardian permission (informed consent) and if appropriate child assent
5. Patient has previously participated in the study
6. Study team is unable to initiate study interventions within the first 24 hours of a patient's admission

Contacts and Locations

Study Contact

Molly E Sonenklar, MD

CONTACT

504-896-9740

msonen@lsuhsc.edu

Casey M Treuting, MD

CONTACT

504-273-3476

ctreu1@lsuhsc.edu

Study Locations (Sites)

Children's Hospital of New Orleans

New Orleans, Louisiana, 70118

United States

Collaborators and Investigators

Sponsor: Louisiana State University Health Sciences Center in New Orleans

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-09-12

Study Completion Date2025-12-19

Study Record Updates

Study Start Date2024-09-12

Study Completion Date2025-12-19

Terms related to this study

Keywords Provided by Researchers

virtual reality
adjunctive therapy
opiate consumption
pain reduction

Additional Relevant MeSH Terms

Sickle Cell Disease
Vaso-occlusive Pain Episodes